Ethyl glucuronide (EtG) determination is increasingly used in clinical and forensic toxicology to document ethanol consumption. The enzymes involved in EtG production, as well as potential interactions with common drugs of abuse, have not been extensively studied. Activities of human liver (HLM), kidney (HKM), and intestinal (HIM) microsomes, as well as of 12 major human recombinant UDP-glucuronosyltransferases (UGTs), toward ethanol (50 and 500 mM) were evaluated in vitro using liquid chromatography-tandem mass spectrometry. Enzyme kinetic parameters were determined for pooled microsomes and recombinant UGTs with significant activity. Individual contributions of UGTs were estimated using the relative activity factor approach, proposed for scaling activities obtained with cDNA-expressed enzymes to HLM. Interaction of morphine, codeine, lorazepam, oxazepam, nicotine, cotinine, cannabinol, and cannabidiol (5, 10, 15 mg/l) with ethanol (1.15, 4.6, 11.5 g/l; i.e., 25, 100, 250 mM) glucuronidation was assessed using pooled HLM. Ethanol glucuronidation intrinsic clearance (Cl int ) was 4 and 12.7 times higher for HLM than for HKM and HIM, respectively. All recombinant UGTs, except UGT1A1, 1A6, and 1A10, produced EtG in detectable amounts. UGT1A9 and 2B7 were the most active enzymes, each accounting for 17 and 33% of HLM Cl int , respectively. Only cannabinol and cannabidiol significantly affected ethanol glucuronidation. Cannabinol increased ethanol glucuronidation in a concentrationdependent manner, whereas cannabidiol significantly inhibited EtG formation in a noncompetitive manner (IC 50 = 1.17 mg/l; inhibition constant (K i ) = 3.1 mg/l). UGT1A9 and 2B7 are the main enzymes involved in ethanol glucuronidation. In addition, our results suggest that cannabinol and cannabidiol could significantly alter ethanol glucuronidation.
Introduction
Alcohol abuse is one of the most frequent addictions worldwide. It is the third leading cause of preventable death in the United States (Mokdad et al., 2004) and also causes many serious social and health problems (Ferreira and Willoughby, 2008) . After oral administration, ethanol is readily absorbed by passive diffusion through the stomach wall (~20%) and the intestine wall (~80%) (Norberg et al., 2003) . Its elimination occurs primarily through metabolism (95%-98%), with minor fractions of the administered dose being excreted unchanged in breath (0.7%), sweat (0.1%), and urine (0.3%) (Holford, 1987) . Ethanol metabolism occurs primarily in the liver, mainly through oxidation catalyzed by alcohol dehydrogenases, aldehyde dehydrogenases, cytochrome P450 2E1, and catalase (Agarwal, 2001; Zakhari, 2006) . Besides these pathways, glucuronidation by UDP-glucuronosyltransferases (UGTs) represents a minor detoxifying pathway for ethanol (,0.1% of complete alcohol elimination) (Jaakonmaki et al., 1967; Dahl et al., 2002; Goll et al., 2002) . Ethanol itself is a good marker of alcohol consumption. However, it has a rapid elimination rate from blood (0.10 to 0.20 g/l/h in occasional drinkers and 0.25 to 0.35 g/l/h in chronic drinkers) (Jones, 2010) , which makes its detection in body fluids only possible during a relatively short time after alcohol intake. Ethyl glucuronide [ethyl-b-D-6-glucuronic acid (ethyl glucuronide) ; EtG] can be detected in various body fluids, tissues, and hair. It is eliminated with a terminal half-life of 2 to 3 hours (Schmitt et al., 1997) and presents a particularly interesting detection window in body fluids (up to 8 hours and 5 days after complete ethanol elimination, in serum and urine, respectively (Schmitt et al., 1997; Wurst et al., 1999) . EtG determination is also much more sensitive and specific than conventional markers (e.g., g-glutamyl transferase, alanine aminotransferase, aspartate aminotransferase, mean corpuscular volume, and carbohydrate-deficient transferrin). It has recently become of more interest in clinical and forensic toxicology. Cutoff for its determination in urine and hair have been reported (Rohrig et al., 2006; Kintz, 2010) . However, considering the numerous factors that could affect glucuronidation (e.g., genetic polymorphisms, inhibition or induction by xenobiotics, and age), the relevance of these cutoffs in clinical and forensic practices can be questioned in certain circumstances (Kiang et al., 2005) . Some reports have indeed documented a high interindividual variability in EtG production (Halter et al., 2008; Paul et al., 2008) . Halter et al. (2007) showed that the administration of a conventional dose of ethanol to 13 individuals resulted in highly variable (8-fold) maximum concentrations of serum EtG, and that EtG concentrations did not correlate with blood ethanol concentrations (Halter et al., 2008) . This marked interindividual variability in EtG levels could be attributed to variable activities of UGTs involved in ethanol metabolism. Because these enzymatic activities are controlled by genetic polymorphisms and can be affected by concomitantly administered drugs (Kiang et al., 2005) , the impact of these factors on EtG production deserves further investigation. The enzymology underlying glucuronidation of ethanol has not received much attention to date. Only one in vitro study by Foti and Fisher (2005) showed that multiple UGTs are likely to be responsible for catalyzing EtG formation, with UGT1A1 and UGT2B7 predominating (Foti and Fisher, 2005) .
The purpose of the present in vitro study was, first, to evaluate qualitatively and quantitatively the specific contribution of UGT enzymes in EtG formation, and second, to study the impact of the coadministration of drugs frequently used by consumers of ethanol [the opioids morphine and codeine; the benzodiazepines oxazepam and lorazepam; the alkaloids found in tobacco, nicotine and cotinine; and the cannabinoids, cannabinol (CBN) and cannabidiol (CBD)] on the production of EtG.
Materials and Methods

Chemicals and Reagents
EtG (reference EGL-332-10) and its deuterated analog EtG-D5 (reference EGL-780-10), which was used as an internal standard, were obtained from Lipomed (Souffelweyersheim, France). Bovine serum albumin (BSA; product number A7906), uridine 59-diphosphoglucuronic acid (UDPGA), dimethylsulfoxide, chenodeoxycholic acid (CDCA), mefenamic acid (MEF), trifluoperazine (TFP), alamethicin, glafenine, morphine, codeine, lorazepam, oxazepam, CBN, CBD, nicotine, and cotinine were obtained from Sigma-Aldrich (Saint-Quentin Fallavier, France). Ethyl alcohol (17 M, 99.8%) and MgCl 2 were purchased from Merck (Darmstadt, Germany). Tris-HCl was obtained from Qbiogene (Illkirch, France), and azidothymidine (AZT) was a kind gift from GlaxoSmithKline (Nanterre, France). Milli-Q water and all solvents were of high-performance liquid chromatography grade.
Microsomes and Enzymes
Human microsomes were prepared from individual liver (n = 44), intestine (n = 19), and kidney (n = 7) samples derived from surgical specimens. Liver and intestine samples were obtained from Biopredic International (Rennes, France), and kidney samples were obtained from the pathology department of Limoges University Hospital. All samples were collected after donors had given their informed consent, in accordance with the French bioethics law. The tissues were microscopically examined by a pathologist to document normal histology; they were then immediately frozen in liquid nitrogen and stored at 280°C until use. Microsomes were obtained by differential centrifugation, as described previously (Picard et al., 2004) . Protein concentration of the microsomal suspensions was measured according to the Bradford's method (Bradford, 1976) . Three pools derived from all individual human liver, intestine, and kidney microsomes (HLM, HIM, and HKM) were prepared.
Membrane fractions from baculovirus-infected insect cells expressing human UGT1A1, 1A3, 1A4, 1A6, 1A7, 1A8, 1A9, 1A10, 2B4, 2B7, 2B15, and 2B17 (BD-Supersomes), as well as a control preparation, were purchased from BD Biosciences Gentest (Woburn, MA).
Incubation Procedures
In preliminary experiments, linearity of EtG formation rate versus microsomal protein concentration (0.5-1 mg/ml) and incubation time (10-75 minutes) was checked by incubating 250 mM ethanol (diluted in Tris-HCl) with HLM (unpublished data). It was also assessed that no major evaporation of ethanol occurred during incubation by comparing ethanol concentrations (25, 100, and 1000 mM) prior to and after 45 minutes at 37°C in the incubation buffer, using a validated gas chromatography-flame ionization detection method (Clarus 480; PerkinElmer, Courtaboeuf, France). Control incubations without substrate, microsomes, or co-substrate (UDPGA dissolved in Tris-HCl) were also performed.
Because K m values (concentrations required to produce 50% of V max ) for substrates of UGT1A9 and 2B7 can be overestimated in the absence of BSA (Rowland et al., 2007 (Rowland et al., , 2008 , incubations with HLM, recombinant UGT1A9, and UGT2B7 were also performed in the presence of 2% BSA. The incubation mixture (100 ml) contained 0.5 mg/ml microsomal proteins (microsomes or BD-Supersomes), 2 mM UDPGA, 10 mM MgCl 2 and 0.1 M Tris-HCl buffer (pH 7.4). Microsomes were first activated by incubation with the pore-forming peptide alamethicin (100 mg/mg microsomal proteins) for 15 minutes on ice. UDPGA and microsomes were then preincubated at 37°C for 5 minutes before starting the reaction by addition of the substrate (5-1000 mM ethanol). After incubating at 37°C for 45 minutes, the reaction was stopped by addition of icecold acetonitrile (50 ml). After centrifugation (10,000g for 5 minutes) to spin down proteins, the supernatant was stored at 220°C until analysis.
Liquid Chromatography-Tandem Mass Spectrometry Analysis
Samples were prepared by adding 20 ml internal standard EtG-D5 solution (2 mg/l in acetonitrile) to 150 ml of incubation supernatants. An aliquot (15 ml) of each sample was then injected into the high-performance liquid chromatographytandem mass spectrometry (LC-MS/MS) system.
Liquid Chromatography. The chromatographic system consisted of a Shimadzu SIL20 AC high-pressure gradient pumping system equipped with two LC20 AD binary pumps, a SIL20-ACHT injector, a CTO-10ASvp column oven, and an Interchim Uptisphere (100 Â 2.1 mm) column (Montluçon, France) maintained at 25°C. The mobile phase, delivered at a constant flow-rate of 200 ml/min, consisted of a linear gradient of solution A (5 mM ammonium acetate, pH 6.8) and solution B (acetonitrile/5 mM ammonium acetate, pH 6.8, 98:2 v/v), as follows: 0-0.1 minute, 5% B; 0.1-1 minute, 5 to 20% B; 1-5 minutes, 20 to 30% B; 5-6 minutes, 30 to 80% B; 6-9 minutes, 80% B; 9-10 minutes, decrease from 80 to 5% B; 10-16 minutes, 5% B.
Mass Spectrometry. Detection was performed using a 4000 QTRAP LC-MS/MS System (ABSciex, Foster City, CA) tandem mass spectrometer equipped with a Turbo V Ionspray source and controlled by Analyst 1.5 software. Negative ionization was performed with the following settings: ion spray voltage, 24500 V; curtain gas, 20; ion source gas flow rates 1 and 2 at 15 and 30 units, respectively; declustering potential, 270 V; and temperature, 500°C.
Acquisition Conditions. Acquisitions were performed in multiple reaction monitoring mode using three transitions for EtG [mass-to-charge (m/z) ratios 221.0→75.0, 221.0→85.0, and 221.0→112.9] and two for EtG-D5 (m/z 226.0→75.0 and 226.0→85.0). Transition m/z 221.0→75.0 was retained for EtG quantification, whereas transitions m/z 221.0→85.0 and 221.0→112.9 were used for identification.
Analytical Validation. The validation parameters were based on the following criteria: specificity, linearity, precision (repeatability and intermediate precision), reproducibility, accuracy, limit of detection, and limit of quantification (LOQ).
Extrapolation of Recombinant UGT Activities
The relative activity factor (RAF) approach is proposed for scaling enzymatic activities obtained using cDNA-expressed enzymes to human microsomes. This approach is well established for cytochromes P450 (Crespi and Miller, 1999) Ethanol Glucuronidation: Enzymes and Potential Interactions 569 at ASPET Journals on July 6, 2017 dmd.aspetjournals.org and has also been used for UGTs (Toide et al., 2004; Rouguieg et al., 2010) . In this study, we calculated RAFs for UGT1A3, 1A4, 1A9, and 2B7 to scale velocities obtained using UGT BD-Supersomes to HLM. CDCA (15 mM), TFP (40 mM), MEF (0.5 mM), and AZT (70 mM) were used as selective substrates for UGT1A3, 1A4, 1A9, and 2B7, respectively. In the case of UGT1A7, 1A8, 2B4, 2B15, and 2B17, RAFs could not be calculated because no adequate probe has been identified to date. Briefly, incubations were performed using the same incubation procedure as previously described except that reactions were terminated by addition of 80 ml of ice-cold methanol containing glafenine (13.5 mM) as an internal standard. Samples were centrifuged at 10000g for 5 minutes at 4°C to pellet the precipitated proteins. CDCA, TFP, MEF, and AZT glucuronides were determined using LC-MS/MS, as described previously (Gagez et al., 2012) . RAF values were calculated by dividing the mean activity of glucuronide formation (n = 2 experiments) obtained in HLM by the mean activity obtained in BD-Supersomes (both expressed in pmol/mg protein/min). The scaled velocities of UGT1A3, 1A4, 1A9, and 2B7 were calculated by multiplying the rate of metabolism observed with these enzymes (V i ) by the corresponding RAF. The contribution (%) of each isoform (contribution i ) was calculated using the following equation:
Chemical Inhibition Experiments
The glucuronidation of ethanol by HLM in the presence of niflumic acid (2.5 mM) and fluconazole (2.5 mM), used as a specific inhibitor of UGT1A9 and UGT2B7, respectively, was investigated (Uchaipichat et al., 2006; Gaganis et al., 2007) . These experiments were conducted in triplicate, as described in "incubation procedures" using 250 mM ethanol. Results are reported as percentages of inhibition of control activities determined in the absence of inhibitor.
Interaction Experiments
The impact of the co-incubation of eight compounds (morphine, codeine, lorazepam, oxazepam, CBN, CBD, nicotine, and cotinine) on HLM-catalyzed ethanol glucuronidation was assessed at three ethanol concentrations (25, 100, and 250 mM; i.e., 1.15, 4.6, and 11.5 g/l). Potentially interacting drugs were tested at three concentrations (5, 10, and 15 mg/l). The effect of CBN and CBD (15 mg/l) on UGT1A9-and UGT2B7-catalyzed ethanol (25 mM) glucuronidation was also assessed. Nicotine and cotinine were dissolved in methanol. Other substrates were dissolved in dimethylsulfoxide. Solvent concentration in the incubation mixture did not exceed 1% (v/v). Incubation and analytical conditions were as previously described. Enzyme activities were compared with those determined in the absence of potentially interacting drugs (control incubation that contained the same volume of solvent). Differences are reported as percentage of control activity derived from triplicate measurements.
Data Analysis
All data points represent the mean of either duplicate or triplicate experiments. Enzyme kinetic parameters were estimated by fitting the MichaelisMenten equation to the data using nonlinear regression (Prism version 5.01; GraphPad Software Inc., La Jolla, CA) and are presented as a regression parameter estimate 6 S.D. of the estimate. The fit of the model to the data was assessed from the Akaike information criterion.
The concentration of the inhibitor required to produce 50% inhibition of the enzymatic activity (IC 50 ) was determined from the curves plotting enzymatic activity versus inhibitor concentrations. The inhibition mechanism was estimated from the figure plotting 1/V versus 1/S. The K i and the mode of inhibition were determined by fitting competitive, uncompetitive, noncompetitive, and mixed inhibition models to the kinetic data using nonlinear regression analysis. The mode of inhibition that best described the data was determined by comparing the fit of various models using the Akaike information criterion. Differences between metabolic rates with and without potential inhibitors were considered significant when P value was less than 0.05. All statistical analyses were performed using nonparametric tests (Kruskall-Wallis or Mann-Whitney) using GraphPad Software.
Results
Analytical Validation. EtG was detected at a retention time of 5.83 minutes following three specific multiple reaction monitoring transitions (Fig. 1) . The quantification limit (LOQ) was 5 ng/ml. Good linearity was observed from the LOQ up to 500 ng/ml (r . 0.999). Intra-and inter-day precisions and mean relative errors showed relative standard deviations that were lower than 10% over the calibration range.
Ethanol Glucuronidation in Human Microsomes. The specific formation of EtG by HLM, HIM, and HKM was confirmed by retention time and MS/MS spectra (Fig. 1) . EtG was not detectable at substrate concentrations lower than 5 mM. Kinetics of ethanol glucuronidation was best fitted by the Michaelis-Menten equation (Fig. 2) . Substrate concentration higher than 1000 mM resulted in a drastic decrease of EtG formation rate, presumably caused by the denaturation of the enzymes (unpublished data). Kinetic parameters, including K m , V max , and intrinsic clearance (Cl int = V max /K m ) for HLM, HIM, and HKM are reported in Table 1 . The three preparations showed very low affinity for ethanol. Maximal formation rate (V max ) and K m were about 1.4-fold and 5.8-fold higher, respectively, with HKM than with HLM. V max and K m were about 27-fold and 2.1-fold lower, respectively, with HIM than with HLM. As a result, the hepatic intrinsic clearance of ethanol appeared 4-fold and about 13-fold higher than that observed with HKM and HIM, respectively. Ethanol Glucuronidation in Recombinant Human UGTs. To identify the human UGTs involved in ethanol glucuronidation, incubations with 12 recombinant UGT enzymes (UGT1A1, 1A3, 1A4, 1A6, 1A7, 1A8, 1A9, 1A10, 2B4, 2B7, 2B15, and 2B17) were performed using 50 mM and 500 mM of ethanol. Our primary results showed that all tested isoforms, except UGT1A1, 1A6, and 1A10, can produce EtG in significant amounts (i.e., . LOQ; Fig. 3 ). UGT2B7 exhibited the highest activity at both concentrations (50 mM and 500 mM) with EtG production of 5.1 and 27.5 pmol/mg protein/min, respectively. The kinetic parameters of EtG production were then determined for the nine UGTs that produced detectable amounts of EtG (Table 1) . EtG production followed the classic Michaelis-Menten equation in all cases. Enzyme kinetics of ethanol glucuronidation by recombinant hepatic UGT enzymes are shown in Fig. 2 . Regarding the potential albumin effect on UGT1A9 and 2B7 activities, 2% BSA had a negligible effect on the kinetics of ethanol glucuronidation by recombinant UGT1A9 and 2B7. K m (and Cl int ) values determined in the absence and presence of BSA were 501 mM (0.103 nl/mg/min) and 407 mM (0.147 nl/mg/min) for UGT1A9, respectively, and 619 mM (0.109 nl/mg/min) and 548 mM (0.152 nl/mg/min) for UGT2B7, respectively.
The relative contribution of UGT1A3, 1A4, 1A9, and 2B7 to EtG production in HLM could be extrapolated using the RAF approach. UGT1A9 and 2B7 were the major contributors (Table 1) ; together these two enzymes were found to account for about 50% of EtG hepatic production. The contribution of UGT1A3 and 1A4 was about 3%.
Effect of Niflumic Acid and Fluconazole on the Glucuronidation of Ethanol by HLM. Niflumic acid and fluconazole produced limited inhibition of ethanol glucuronidation in HLM (9% 6 5% and 18% 6 9%, respectively).
Effect of Common Drugs of Abuse on the Glucuronidation of Ethanol by HLM. Among all the drugs tested (morphine, codeine, lorazepam, oxazepam, CBN, CBD, nicotine, and cotinine), only CBN and CBD significantly affected ethanol glucuronidation (Fig. 4) . CBN significantly increased the glucuronidation of ethanol in a concentration-dependent manner ( Fig. 4C ; Kruskall-Wallis test: P , 0.05); CBD, however, significantly inhibited EtG production, with an IC 50 value of 1.17 mg/l ( Fig. 4C ; Kruskall-Wallis test: P , 0.05). Inhibition kinetics demonstrated a noncompetitive inhibition, with a K i of 3.1 mg/l (Fig. 5) . To identify which UGT was involved in these effects, we assessed the impact of CBN or CBD (15 mg/l) on the glucuronidation of ethanol (25 mM) by recombinant UGT1A9 and 2B7. UGT1A9 was inhibited by both CBN and CBD (234% 6 12% and 249% 6 14%, respectively; P = 0.05). On the other hand, the activity of UGT2B7 was significantly increased by CBN (+429% 6 112%; P = 0.05), whereas it was inhibited by CBD (270% 6 7%; P = 0.05; unpublished data).
Discussion
Using human microsomes, we showed that liver, intestine, and kidney can produce EtG. The Cl int of HLM was 4 times and 13 times higher than those of HKM and HIM, respectively, which strongly suggests that ethanol is primarily glucuronidated by the liver, and that kidney and intestine tissues play only minor roles in this metabolic pathway. The low affinity of ethanol for liver UGTs observed here is in accordance with data published by Jurowich et al. (2004) , who found similar values of K m using HLM (373.4 6 47.6 mM versus 1082 6 343.3 mM) (Jurowich et al., 2004) . It is also in the range of the affinities obtained with recombinant enzymes (from 133 mM for UGT2B17 to 1706 mM for UGT1A4). In contrast, Foti and Fisher (2005) reported an apparent K m of 0.17 6 0.08 mM using HLM. We have no clear explanation for this discrepancy. It could possibly be attributed to differences in experimental conditions, such as the type of reagent use to circumvent UGT latency dimethylammonio]-1-propanesulfonic acid)], the absence of normalization of enzyme activity with UGT content, and more importantly, the range of tested ethanol concentrations.
In humans, EtG represents less than 0.1% of complete ethanol elimination. It seems thus logical that the affinity for UGT enzymes is less than that for hepatic alcohol dehydrogenase (K m = 0.2 to 2.0 mM) and cytochrome P450 2E1 (K m = 10 mM), two enzymes with a major role in ethanol metabolism (Zakhari, 2006; Hamitouche et al., 2006) .
Although multiple UGTs (especially UGT1A1 and 2B7) have already been highlighted as competent isoforms for EtG hepatic formation (Foti and Fisher, 2005) , their specific contributions were unclear. Using the RAF approach, we evaluated quantitatively the role of UGT1A3, 1A4, 1A9, and 2B7. RAFs were calculated from metabolic rates obtained by incubating CDCA, TFP, MEF, and AZT with recombinant enzymes and pooled HLM. The choice of these substrates and their tested concentrations was supported by the literature (Court, 2005; Trottier et al., 2006) , as well as by a recent study conducted in our group (Gagez et al., 2012) . We found that UGT1A9 and UGT2B7 were responsible for approximately 17% and 32% of liver ethanol glucuronidation, respectively. Niflumic acid and fluconazole are considered to be specific inhibitors of UGT1A9 and 2B7, respectively (Uchaipichat et al., 2006; Gaganis et al., 2007) . They produced only moderate inhibition of ethanol glucuronidation by HLM, suggesting an implication of the two UGTs of approximately 30%. However, ethanol was tested at a concentration 10000-and 100-fold higher than those of UGT1A9 and 2B7 inhibitor, respectively. It is possible that ethanol could overcome competitive inhibitions.
BSA is known to affect the kinetics of UGT1A9 and 2B7 (Rowland et al., 2007 (Rowland et al., , 2008 . Consistent with previous observations, we observed a decrease in enzyme K m and a consecutive increase of Cl int , but this effect was limited. The nonspecific binding of ethanol to BSA could result in a falsely elevated estimation of the K m , but this seems unlikely because ethanol has not been reported to bind to albumin (at least not in vivo). Another possible explanation is that we did not use fatty acid-free BSA, which would presumably have resulted in a more accurate estimation of the kinetic parameters. Nonetheless, a more pronounced BSA effect would only have strengthened our conclusion on the predominant role of UGT1A9 and 2B7.
The RAF approach predicted a limited role of UGT1A3 and 1A4 (;3%) in EtG hepatic production. Because of the absence of specific substrates for UGT2B4, 2B15, and 2B17, we could only hypothesize that these isoforms would account for the remaining part of ethanol glucuronidation in HLM. Because UGT1A7 and 1A8 are not expressed in the liver (Ohno and Nakajin, 2009; Court et al., 2012) and no specific substrates are available for these UGTs, their contribution to ethanol glucuronidation could not be precisely assessed. Furthermore, as some human UGTs are not commercially available as recombinant enzymes, several other hepatic and extrahepatic UGTs (including UGT1A5, 2B10, 2B11, 2B28, 2A1, 2A2, and 2A3) were not studied and their contribution toward EtG formation cannot be ruled out. Considering their low expression levels in human liver, kidney, and intestine, their contribution to at ASPET Journals on July 6, 2017 dmd.aspetjournals.org ethanol metabolism is likely to be minor (Ohno and Nakajin, 2009; Sneitz and others, 2009; Court et al., 2012) .
We found almost no activity with UGT1A1 (EtG formation rate , LOQ), which contradicts the data of Foti and Fisher (2005) . This discrepancy could possibly be attributed to the different commercial sources of UGT used. We could not test this hypothesis as the Panvera UGT1A1 Baculosomes (used by Foti and Fisher, 2005) was no longer available at the time of the present study.
Another possible confounding factor is the effect of ethanol on UGT activities. Ethanol (.0.5% v/v) can substantially inhibit UGT2B17 and 1A6 (Uchaipichat et al., 2004) . Our initial screening for competent UGTs was performed using 0.3% and 3% v/v ethanol (i.e., 50 and 500 mM). We cannot exclude the possibility that the activity of UGT2B17 and UGT1A6 had been underestimated. However, it is unlikely that other UGTs, and specifically UGT1A1, had been affected in particular when using 0.3% v/v ethanol. On the other hand, kinetic experiments required up to 6% of ethanol (v/v), which possibly influenced the estimation of kinetic parameters for other UGTs.
Several drugs are inhibitors of UGT-mediated glucuronidation (Kiang et al., 2005) , but drug interactions with ethanol glucuronidation have not been studied so far. Paul et al. (2008) compared the mean concentration of EtG in hair samples between a group of narcotic and drug consumers (opiates, cocaine, amphetamines, methamphetamine, benzodiazepines, and cannabis) and a group of non-consumers. The mean concentration of EtG was significantly higher in the drugnegative group than that found in the drug-positive group (0.107 versus 0.011 ng/mg; P , 0.05) (Paul et al., 2008) . To better understand such possible interactions, we used pooled HLM to perform in vitro co-incubations of ethanol with various compounds frequently used by alcohol consumers. The eight potential inhibitors tested here were known UGT substrates. Morphine and codeine are metabolized by UGT2B7 (Coffman et al., 1997) , and lorazepam and oxazepam by UGT2B7 and 2B15 (Court et al., 2002; Chung et al., 2008) . CBN is metabolized with high affinity by UGT1A9 and is also substrate for UGT2B7 and the extra-hepatic UGT1A7 and 1A10 (Mazur et al., 2009) . CBD is metabolized less intensively than CBN by UGT1A9, UGT2B7, and UGT2B17 (Mazur et al., 2009) . Finally, nicotine is a substrate for UGT1A4, 2B10, and 2B7, and cotinine for UGT1A4 and 2B10 (Kaivosaari et al., 2007) .
Inhibition screening studies were performed at ethanol concentrations of 25, 100, and 250 mM (i.e., 1.15, 4.6, and 11.5 g/l), which are lower than the apparent K m of HLM and close to expected blood concentrations in the context of abusive intake of alcoholic beverages. Morphine, codeine, and benzodiazepines were tested at concentrations ranging from 1 to 30 times the blood levels usually encountered in clinical or toxicologic settings. Morphine, codeine, nicotine, and cotinine did not modify EtG in vitro formation rate. Lorazepam and oxazepam produced a minor, but not significant, increase of EtG formation by HLM. These results tend to exclude a potential effect of these drugs on ethanol glucuronidation in vivo, in particular at lower therapeutic or toxic levels. In contrast, CBD exhibited a strong noncompetitive inhibition of ethanol glucuronidation, which could be attributed to the inhibition of both UGT1A9 and 2B7. On the other hand, CBN increased ethanol glucuronidation in a concentrationdependent manner, which appears to result from the modulation of UGT2B7 activity. Although heterotropic activation of UGT2B7 has been demonstrated (Uchaipichat et al., 2008) , the precise mechanism of interaction between UGT2B7-catalyzed CBN and ethanol glucuronidations remains to be further investigated. In addition, it is noteworthy that the cannabinoid concentrations used here are very likely exceeding expected in vivo concentrations. It is well known that CBN and CBD contents vary widely in various cannabis sources, but scarce information is available on their blood and tissue concentrations dmd.aspetjournals.org in cannabis consumers. Recently, median plasma maximum concentrations were reported to be about 2.0 mg/l for CBD and 3.6 mg/l for CBN after smoking one 6.8% tetrahydrocannabinol cannabis cigarette (Schwope et al., 2011) . However, plasma or whole-blood cannabinoid concentrations do not reflect tissue concentrations, particularly liver concentrations, which can be largely higher for CBD and CBN (Gronewold and Skopp, 2011) . Consequently, the relevance of this cannabinoid/ethanol interaction on EtG formation remains uncertain and needs to be further investigated.
Other sources of interaction with EtG levels might also exist and were not studied here. One can hypothesize that EtG renal elimination involves active efflux transporters and that competitive inhibition of these transporters by glucuronides of other drugs of abuse can occur.
In conclusion, UGT1A9 and 2B7 are predominantly involved in ethanol glucuronidation (50% of the overall EtG formation) and appear to be differently affected by high concentrations of cannabinoid compounds. Additional studies are required to assess the potential contribution of UGT1A9 and 2B7 genetic polymorphisms, as well as of cannabis consumption, to the inter-individual variability of EtG production.
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